2017
DOI: 10.1016/j.blre.2016.09.004
|View full text |Cite
|
Sign up to set email alerts
|

High grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6: Double hit and triple hit lymphomas and double expressing lymphoma

Abstract: Diffuse large B-cell lymphomas with aberrations in MYC, BCL2 and/or BCL6 by genetic alterations or protein expression represent a group of high grade B-cell lymphomas with inferior outcomes when treated with standard RCHOP chemotherapy. As a result, intensified induction regimens have been suggested in an effort to improve outcomes. Conclusions to date have largely been drawn from retrospective data although prospective data is slowly starting to emerge. Chemoimmunotherapy refractoriness is problematic and rel… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

8
141
0
6

Year Published

2017
2017
2023
2023

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 185 publications
(155 citation statements)
references
References 48 publications
8
141
0
6
Order By: Relevance
“…Though over‐represented compared with a systemic DLBCL population, IHC‐defined non‐GC subtype was relatively less frequent when compared to PCNSL, where the vast majority are ABC subtype (Rubenstein, ). This may be partly explained by the relatively high percentage of HGBL‐DH in our cohort (23% of cases tested), which are usually GC phenotype and have CNS risk (Rosenthal & Younes, ). Ultimately, gene expression profiling and analysis of the genetic and functional drivers is required to optimally define this entity.…”
Section: Discussionmentioning
confidence: 94%
“…Though over‐represented compared with a systemic DLBCL population, IHC‐defined non‐GC subtype was relatively less frequent when compared to PCNSL, where the vast majority are ABC subtype (Rubenstein, ). This may be partly explained by the relatively high percentage of HGBL‐DH in our cohort (23% of cases tested), which are usually GC phenotype and have CNS risk (Rosenthal & Younes, ). Ultimately, gene expression profiling and analysis of the genetic and functional drivers is required to optimally define this entity.…”
Section: Discussionmentioning
confidence: 94%
“…Although expression of MYC-IHC in >40% neoplastic cells and the BCL-2 in >50% have been indicated as prognostically significant cut-offs in many reports, the degree of agreement among haematopathologists for these thresholds has only moderate concordance 3,4 . Standardizing cut-offs to define positivity for MYC-IHC and BCL-2-IHC with higher reproducibility and prognostic impact is thus highly desirable for optimizing patients' management 5,6 .…”
mentioning
confidence: 99%
“…Furthermore, Myc, Bcl2, and Bcl6 were detected in all patients by immunohistochemistry. For patients included in the present study, the positive cut‐off value of Myc was set at >40%, the positive cut‐off value of Bcl2 was set at >50%, and the positive cut‐off value of Bcl6 was set at >30% . In addition, the CD10, Bcl6, GCET‐1, FOXP1, and MUM1 were detected in pathological specimens obtained from patients by immunohistochemistry, and COO was differentiated using the Han or Choi models.…”
Section: Methodsmentioning
confidence: 99%